The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies

Blood Cancer Journal

Volumn 1, Issue 10, 2011, Pages

  Van Der Veer, M S ^a   De Weers, M ^b   Van Kessel, B ^a   Bakker, J M ^b   Wittebol, S ^c   Parren, P W H I ^b   Lokhorst, H M ^a   Mutis, T ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Meander Medical Center ^*

^c MEANDER MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DARATUMUMAB; FLUDARABINE; LENALIDOMIDE;

ANTINEOPLASTIC ACTIVITY; CLINICAL ARTICLE; CLINICAL PRACTICE; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LETTER; MULTIPLE MYELOMA;

EID: 84864061825     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2011.42     Document Type: Letter

References (9)

1. Brenner H, Gondos A, Pulte D. Recent major improvement in longterm survival of younger patients with multiple myeloma. Blood 2008; 111: 2521-2526.
2. Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Blade J et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011; 117: 6063-6073.
3. Orlowski RZ, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007; 25: 3892-3901. (Pubitemid 47477266)
4. Hallek M, Pflug N. State of the art treatment of chronic lymphocytic leukaemia. Blood Rev 2011; 25: 1-9.
5. Ahmadi T, Chong EA, Gordon A, Leinbach L, Aqui NA, Nasda SD et al. Phase II trial of lenalidomideFdexamethasoneFrituximab in relapsed or refractory indolent B-cell or mantle cell lymphomas resistant to rituximab. Blood (ASH Annual Meeting Abstracts) 2010; 116: 3962.
6. de Weers M, Tai YT, van der Veer M, Bakker JM, Vink T, Jacobs DC et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011; 186: 1840-1848.
7. van der Veer M, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 2011; 96: 284-890.
8. Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 2010; 28: 2612-2624.
9. Ludwig H, Beksac M, Blade J, Cavenagh J, Cavo M, Delforge M et al. Multiple myeloma treatment strategies with novel agents in 2011: a European perspective. Oncologist 2011; 16: 388-403.